Insu Therapeutics has secured a US patent allowance for its buccal delivery platform, but its needle-free insulin and semaglutide treatments remain investigational and require clinical and regulatory approval.
Victory Square Technologies said Insu Therapeutics has received a notice of allowance from the United States Patent and Trademark Office for patent protection covering its buccal peptide-delivery platform, a step the company says strengthens the intellectual-property base behind its lead programmes, InsuTab and BuccaGLP. The allowance does not mean a patent has yet been issued, and the company said formal grant still depends on fee payment and completion of remaining administrative steps.
The Vancouver-based Insu is developing formulations intended to deliver peptide medicines through the lining of the cheek rather than by injection or swallowing. Its first two programmes use insulin and semaglutide, a GLP-1 medicine that has become central to diabetes and weight-management treatment. Insu said the approach is designed to offer a needle-free alternative and to avoid some of the dosing constraints associated with certain oral peptide drugs. The company also said it has completed laboratory, cell-culture and rat studies at the University of British Columbia as proof of concept for the insulin candidate.
The firm’s wider commercial position rests in part on an exclusive worldwide licence from the University of British Columbia, which gives it rights to develop, market, commercialise and sublicense the technology. Insu said related patent filings are also under way in other jurisdictions, while Victory Square said Hydreight Technologies has already disclosed exclusive United States distribution rights for peptide therapeutics using the same buccal platform, subject to development and regulatory approval. Hydreight separately disclosed a strategic investment in Insu earlier this year, underscoring how the two companies are trying to link drug-delivery research with a possible sales channel in the United States.
Victory Square chief executive Shafin Diamond Tejani said the patent milestone advances the foundation of the business and sits alongside the university licence and Hydreight’s distribution rights. Insu board chair and co-founder Anubhav Pratap-Singh said the group’s aim is to turn the research into practical needle-free versions of insulin and semaglutide. Even so, the company acknowledged that the products remain investigational, that patent allowance does not prove safety or efficacy, and that any eventual commercial path would still depend on clinical development, manufacturing readiness and regulatory clearance. Insu also pointed to wider market growth in GLP-1 medicines, although that forecast relates to the broader category rather than any assured return for the company.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
